Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists. Issue 5 (9th March 2022)

• Record Type: Journal Article
• Authors: Goldenberg, Ronald M.; Cheng, Alice Y.Y.; Fitzpatrick, Tess; Gilbert, Jeremy D.; Verma, Subodh; Hopyan, Julia J.
• Is Part Of: Stroke. Volume 53:Issue 5(2022)
• Page Start: 1813
• Page End: 1822
• Publication Date: 2022-03-09
• Subjects: diabetes mellitus, type 2 -- glucagon-like peptide-1 receptor -- hypoglycemic agents -- ischemic stroke; Cerebrovascular disease -- Periodicals; Cerebral circulation -- Periodicals; 616.81
• DOI: 10.1161/STROKEAHA.121.038151
• Languages: English
• ISSNs: 0039-2499

Abstract

Abstract : People living with diabetes are at higher risk for stroke and have a poorer prognosis following a stroke event than those without diabetes. Data from cardiovascular outcome trials and meta-analyses indicate that GLP-1RAs (glucagon-like peptide 1 receptor agonists) reduce the risk of stroke in individuals with type 2 diabetes. Accordingly, many guidelines now recommend the addition of GLP-1RAs to ongoing antihyperglycemic regimens to lower the risk of stroke in type 2 diabetes. The current work summarizes evidence supporting the use of GLP-1RAs for stroke reduction in people with type 2 diabetes and offers 2 new resources for neurologists who are considering GLP-1RAs for their patients—a list of frequently asked questions with evidence-based answers on safely initiating and managing GLP-1RAs, and a practical decision-making algorithm to assist in using GLP-1RAs as part of a stroke reduction strategy.